Hot Investor Mandate 18: Family Office Invests Early in Novel Therapeutics, Devices and Life Science Tools

21 Sep

A family office based in California invests in primarily early-stage (seed, Series A) companies with truly innovative technologies with a typical investment size of $2-5M per company and can invest as low as $500K. The firm will generally lead investments, and invests globally with no geographic preference.

The firm is seeking innovative technology that is outside traditional biotech. The company is agnostic across life science sectors, including therapeutics, devices, and tools, but will not look at Healthcare IT or digital health technologies. They are interested in therapeutics targeting novel first-in-class targets, and not in biosimilars or repurposed drugs. The firm focuses on early stage preclinical to clinical-stage technology, though may be open to commercial-stage technology depending on the opportunity.

The firm is seeking companies with founders who have big ambitions, and a demonstrated ability to sell their team, investors, and partners on their vision. Previous startup experience is a big plus, but not required, and they will invest in young and first-time entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: